Navigation Links
Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
Date:10/31/2013

September 30, 2013 (In thousands) Three Months Ended 4.1Cost of goods sold (a)September 30,2013as reportedGAAP%of productsales2013fair valuestep-upadjustment toinventory andother non-GAAP (b)2013excluding fairvalue step-upadjustmentto inventoryand othernon-GAAP%of productsalesDeveloped Markets$
374,30534%$
26,559$
247,74622%Emerging Markets186,55048%32,650153,90039%$
560,855
37%$
59,209
$
401,646
27% Nine Months Ended September 30,2013as reportedGAAP%of productsales2013fair valuestep-upadjustment toinventory andother non-GAAP (c)2013excluding fairvalue step-upadjustmentto inventoryand othernon-GAAP%of productsalesDeveloped Markets$
701,77526%$
207,846$
493,92919%Emerging Markets427,16745%44,312382,85540%$ 1,128,94231%$
252,158
$
876,784
24%(a) See footnote (a) to Table 2a.(b) Developed Markets include $122.2 million of fair value step-up adjustment to inventory, $3.1 million of integration related tech transfer costs and $1.5 million BMS fair value inventory adjustment offset by PP&E step down of $0.2 million.  Emerging Markets include $27.2 million of fair value step up adjustment to inventory, $4.2 million of integration related tech transfer costs and $1.2 million of PP&E step up and other.(c) Developed Markets include $187.8 million of fair value step-up adjustment to inventory, $15.8 million of integration related tech transfer costs and $5.0 million BMS fair value inventory adjustment offset by PP&E step down of $0.8 million.  Emerging Markets include $31.4 million of fair value step up adjustment to inventory, $9.6 million of integration related tech transfer costs and $3.3 million of PP&E step up and other. Valeant Pharmaceuticals International, Inc.Table 5Consolidated Balance Sheet and Other D
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: Sepsis ... Sepsis patients suffer from a series of diverse ... toxins in the blood or tissues, which cause a ... leading to mortality rates near 50% depending on disease ... national healthcare systems of the global marketplace, which for ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: ... Forecast and Market Analysis to 2022 - Event-Driven Update ... dominated by generics and GlaxoSmithKline,s Benlysta is the only ... more than 50 years. Following Benlysta,s launch, patients, uptake ... price-tag Benlysta has managed to grow the lupus market ...
(Date:5/27/2015)... May 27, 2015 ... the addition of the  "Asia Pacific Ultrasound ... (2014 - 2019)"  company profile to ... , , ,Ultrasound is a type of ... look at body parts and structures inside ...
Breaking Medicine Technology:OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... BMR, TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - ... the,development and commercialization of cancer therapies, today,announced ... team in,Basel, Switzerland validates tenascin as an ... treatments for glioblastoma,multiforme (GBM). , The researchers ...
... BioPharma, Inc.,(Nasdaq:AVII) announced today that its partner Cook ... data from a Phase II clinical trial known ... was designed to study,the effect of the Neugene(R) ... placement of one or more bare metal,stents, in ...
Cached Medicine Technology:Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 2Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 3Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 4AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2
(Date:5/27/2015)... May 27, 2015 In support of ... 2015 issue of the Journal of American Geriatrics Society ... abdominal obesity, Bedford Commons OB-GYN P.A . is ... non-nutritive sweetener-flavored beverages. , To examine the relationship ... comprehensive San Antonio Longitudinal Study of Aging (SALSA) tracked ...
(Date:5/27/2015)... May 27, 2015 The Case ... a partnership to provide CMSA's Career and Knowledge ... collaboration seeks to strengthen the case/care management workforce ... CKP program. The mutually beneficial agreement provides Medix, ... skills of talent in the healthcare, scientific and ...
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 ... the first healthcare provider along the Gulf Coast ... management (CCM). In partnership with MD Revolution, a ... a new program that enables healthcare providers to ... reimbursements. This new, user-friendly program is designed to ...
(Date:5/27/2015)... CompanionDx announced that its ... analysis in personalized cancer therapy: Non-small cell lung cancer ... of Clinical Oncology (ASCO) as part of their annual ... The molecular and clinical data used for the study ... The study reports improved patient outcomes from a preliminary ...
(Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
Breaking Medicine News(10 mins):Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2
... 10 Warner Chilcott plc (Nasdaq: WCRX ) ... lawsuits against Lupin Limited and its wholly owned subsidiary Lupin ... District of Delaware for infringement of Warner Chilcott,s U.S. Patent ... which cover oral contraceptives LOESTRIN 24 FE and FEMCON FE, ...
... to treat major depression. Many antidepressant medications are available, but no ... right for an individual. As a result, for more than half ... can take months to figure out what does. Now, based ... clinicians may be able to accurately predict within a week whether ...
... The University of Miami School of Nursing and Health Studies ... Foundation in the amount of $30,000 to support six students ... program. "Family nurse practitioners have a promising future" said Nilda ... Studies. "The Dr. John T. Macdonald Foundation grant will help ...
... threat, just like swine flu , THURSDAY, Sept 10 (HealthDay News) ... flu poses a real threat this fall, too. , And the ... Then follow it up with an H1N1 swine flu vaccine when ... Thursday from U.S. health officials, who noted that seasonal flu puts ...
... , , , ... and breadth of the H1N1 virus - the upcoming revisit of ... dangerously low preparedness plans within the private sector. "There,s no question ... Kineo Group. "Businesses are navigating a daunting market and obstacles not ...
... PEMBROKE, Bermuda, Sept. 10 Allied ... announced today that Allied,World,s Chief Operating Officer, David Bell, ... Symposium at the Cityplace Conference Center in,Dallas, Texas on ... Entrepreneurial Insurance Symposium is organized by MarketScout, and,the theme ...
Cached Medicine News:Health News:Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents 2Health News:Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents 3Health News:Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents 4Health News:UCLA researchers develop biomarker for rapid relief of major depression 2Health News:UCLA researchers develop biomarker for rapid relief of major depression 3Health News:UM receives grant to support graduate students in the family nurse practitioner program 2Health News:Get Your Vaccine for Seasonal Flu, Experts Urge 2Health News:Get Your Vaccine for Seasonal Flu, Experts Urge 3Health News:H1N1 Swine Flu Preparedness Uncertainty Results in Higher Business Disruption Risk 2Health News:Allied World's David Bell to Present as Keynote Speaker at 2009 Entrepreneurial Insurance Symposium 2Health News:Allied World's David Bell to Present as Keynote Speaker at 2009 Entrepreneurial Insurance Symposium 3
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... lets you sleep on your ... the morning awake with your ... to take on the day. ... and protection, this preservative-free lubricant ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
Medicine Products: